Menu Search
Equities

BIOTEST PRF

  • Add to watchlist
  • Add to portfolio
  • Add an alert
0N70:LSE

BIOTEST PRF

Actions
  • Price (EUR)31.80
  • Today's Change31.80 / --
  • Shares traded1.40k
  • 1 Year change--
  • Beta-0.0804
Data delayed at least 15 minutes, as of Feb 09 2026 07:43 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Biotest AG is a Germany-based provider of plasma proteins and biological drugs. The Company, with a chain that extends from pre-clinical and clinical development to worldwide marketing and distribution, mainly specializes in the areas of clinical immunology, hematology, and intensive care medicine. It develops, manufactures, and markets immunoglobulin, coagulation factors, and albumins based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. In addition, the Company develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus, which are produced by recombinant technologies.

  • Revenue in EUR (TTM)635.20m
  • Net income in EUR-24.50m
  • Incorporated2006
  • Employees2.50k
  • Location
    BIOTEST PRFLandsteinerstr. 5DREIEICH 63303GermanyDEU
  • Phone+49 61038010
  • Fax+49 6 103801150
  • Websitehttps://www.biotest.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.